Nasopharyngeal stenosis: about mucocutaneous leishmania
Article Sidebar
Main Article Content
Abstract
Leishmaniasis is an intracellular protozoan disease. One of its forms of presentation is mucocutaneous, which is sequela of cutaneous leishmania and only occurs in 1% to 5% of those who suffer it. It affects the nasal, pharyngeal and laryngeal mucosa, causing dyspnea and dysphagia. We presented a case of a 76-year-old patient with obstructive nasal symptoms, who evidenced multiple nasal and pharyngolaryngeal
synechiae. Given the clinical suspicion of the disease, it is important to remember that the diagnosis is made through the Montenegro intradermal reaction and or indirect immunofluorescence titers greater than 1:16, and the treatment includes pentavalent antimonial, one of the most used; however, it has a high degree of recurrence and side effects, so amphotericin B becomes the treatment of choice. In some cases, surgical management can be very useful for the improvement of symptoms caused by the disease.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Este artículo es publicado por la Revista Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello.
Este es un artículo de acceso abierto, distribuido bajo los términos de la LicenciaCreativeCommons Atribución-CompartirIgual 4.0 Internacional.( http://creativecommons.org/licenses/by-sa/4.0/), que permite el uso no comercial, distribución y reproducción en cualquier medio, siempre que la obra original sea debidamente citada.
eISSN: 2539-0856
ISSN: 0120-8411
References
Di Lella F, Vincenti V, Zennaro D, Afeltra A, Baldi A, Giordano D, et al. Mucocutaneous leishmaniasis: report of a case with
massive involvement of nasal, pharyngeal and laryngeal mucosa. Int J Oral Maxillofac Surg. 2006;35(9):870-2. doi:
1016/j.ijom.2006.02.015.
David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22(6):491-502. doi:
1111/j.1529-8019.2009.01272.x.
Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA. Mucosal leishmaniasis: description of
case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol. 2009;23(9):1026-34. doi: 10.1111/j.1468-3083.2009.03238.x.
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007;44(3):350-6. doi: 10.1086/510588.
da Costa DC, Palmeiro MR, Moreira JS, Martins AC, da Silva AF, Madeira Mde F, et al. Oral manifestations in the American
tegumentary leishmaniasis. PLoS One. 2014;9(11):e109790.doi: 10.1371/journal.pone.0109790.
Guía protocolo para la vigilancia en salud pública de leishmaniasis. Ministerio de la Protección Social, Instituto
Nacional de Salud; 2013. Consultado noviembre de 2020 [consultado el falta la fecha en que el autor consultó el enlace].
Disponible en: https://www.minsalud.gov.co/Documents/ Salud%20P%C3%BAblica/Ola%20invernal/protocolo%20
LEISHMANIASIS.pdf
Guía de atención de la leishmaniasis. Medicina & Laboratorio.2011;17(11-12):553-80.
Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti
Infect Ther. 2010;8(4):419-33. doi: 10.1586/eri.10.19.
Palumbo E. Treatment strategies for mucocutaneous leishmaniasis. J Glob Infect Dis. 2010;2(2):147-50. doi:
4103/0974-777X.62879.
Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am. 2012;26(2):293 307.doi: 10.1016/j.idc.2012.03.001. (Nota: esta referencia no tiene
llamado dentro del texto)